Latest Breaking News On - Reinhard zeidler - Page 1 : vimarsana.com

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

ITM, Helmholtz Munich and University Hospital Münster

A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of...

ITM, Helmholtz Munich and University Hospital Münster

Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company,...

ITM Isotope Technologies Munich SE: ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

Garching/Munich, Munich and Münster, Germany, March 13, 2023 - ITM Isotope Technologies Munich SEand the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster today announced

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme | More News

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

ITM Isotope Technologies Munich SE: ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

Investigator-initiated multicenter Phase I study in glioblastoma with CAXII-targeting, 177Lu radiolabeled antibody Fab fragment (LuCaFab) in preparation, led by University of Münster as the sponsor